This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Drugs

Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings

Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

04/17/14 - 09:18 AM EDT

Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.

04/16/14 - 08:00 AM EDT

Try Jim Cramer's Action Alerts PLUS
Markets Rise on Strong Earnings But Underlying Weakness Persists

Markets Rise on Strong Earnings But Underlying Weakness Persists

Markets closed higher after strong earnings for Coca-Cola and Johnson & Johnson, though unrest continued in Ukraine and concerns are rising on the outlook for Chinese economic growth.

04/15/14 - 04:25 PM EDT

Article
Earnings Countdown: Intel, Yahoo!, CSX, Abbott Labs

Earnings Countdown: Intel, Yahoo!, CSX, Abbott Labs

CSX Corp and Abbott Labs complete the four companies that report after the close today or before the opening bell on Wednesday.

04/15/14 - 08:47 AM EDT

Article
Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

Investors say Johnson & Johnson's earnings beat will take the Dow and the biotech sector higher today.

04/15/14 - 11:04 AM EDT

Article
Jim Cramer: A Bizarro-World Market

Jim Cramer: A Bizarro-World Market

It's unnerving that almost every strong stock has a poorly performing company underneath it.

04/14/14 - 11:28 AM EDT

Article
Rite Aid Gets Profit Boost From Growing Pharmacy Same-Store Sales

Rite Aid Gets Profit Boost From Growing Pharmacy Same-Store Sales

  • Tickers in this article:
  • RAD

Shares of Rite Aid are climbing on Thursday after the drugstore chain reports higher-than-expected profit for the fourth quarter and issues a 2015 earnings forecast above analysts' estimates. Rite Aid forecast full-year 2015 sales of $26 billion to $26.5 billion, beating analysts' forecasts of revenue of about $25.7 billion. The company said it expects its pharmacy sourcing deal with McKesson as well as new and higher-priced generic drugs to drive sales in 2015.

04/10/14 - 11:00 AM EDT

Video
Shares of Rite Aid Soar After Trumping Analysts' 2015 Forecasts Shares of Rite Aid Soar After Trumping Analysts' 2015 Forecasts
  • Tickers in this article:
  • RAD

Rite Aid said it expects its pharmacy sourcing deal with McKesson as well as new and higher-priced generic drugs to drive sales in 2015.

04/10/14 - 10:41 AM EDT

Video
Marijuana Stocks Need to Grow Their Balance Sheets Marijuana Stocks Need to Grow Their Balance Sheets

Penny stock publisher Peter Leeds finds most pot companies to be very high risk and cautions investors to wait until prices drop.

04/09/14 - 03:08 PM EDT

Article
Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.

04/09/14 - 10:06 AM EDT

Article
Intuitive Surgical's Robots Don't Play Well With Each Other and Docs are Pissed

Intuitive Surgical's Robots Don't Play Well With Each Other and Docs are Pissed

  • Tickers in this article:
  • ISRG

An inside look at how Intuitive Surgical botched the upgrade cycle for its high-price surgical robots.

04/08/14 - 09:34 AM EDT

Article
Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment

Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment

  • Tickers in this article:
  • ALKS
  • JNJ

If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otuska and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year.

04/08/14 - 09:11 AM EDT

Article
April 8 Premarket Briefing: 10 Things You Should Know

April 8 Premarket Briefing: 10 Things You Should Know

U.S. stock futures point to a slight rebound on Wall Street; Citigroup to pay $1.13 billion to settle mortgage claims; Japan's Takeda and Eli Lilly are ordered to pat $9 billion in diabetes-drug case; Alcoa to report earnings on Tuesday.

04/08/14 - 07:55 AM EDT

Video
Mallinckrodt Gets Money-Making Acthar Gel by Acquiring Questcor Mallinckrodt Gets Money-Making Acthar Gel by Acquiring Questcor
  • Tickers in this article:
  • MNK
  • QCOR

Mallinckrodt will gain Questcor's lucrative drug Acthar Gel, which treats autoimmune and inflammatory diseases. Sales of the drug jumped about 50% year-over-year in 2013.

04/07/14 - 01:15 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs